Immunome Inc. (IMNM): Capital Expenditures
$9.69M
Year ended 2025-12-31
$10.29M
Trailing 12 months to 2026-06-30
+239.3%
3-year compound annual growth
+75.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.69M | +35.0% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $7.17M | +763.2% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $831.0K | +235.1% | 2025-03-19, From 2023-01-01 |
| 2022-12-31 | $248.0K | +213.9% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $79.0K | -86.5% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $586.0K | +151.5% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $233.0K | n/a | 2021-03-25, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Immunome Inc. (IMNM) | 2025-12-31 | $9.69M | +35.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $0 | -100.0% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $799.0K | -74.0% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $518.0K | -97.1% |
| Adagene Inc. (ADAG) | 2025-12-31 | $17.1K | -49.2% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $72.0K | +75.6% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $111.0K | -8.3% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.21M | +78.5% |
Compare IMNM, WHWK, OVID, XENE side by side · Screen every company in Pharmaceutical Preparations ↗